News

NEW YORK, NY, and CARLSBAD, CA, January 9, 2023 - Royalty Pharma plc (Nasdaq: RPRX) and Ionis Pharmaceuticals, Inc. (Nasdaq: IONS) today announced that Royalty Pharma has acquired an interest in Ionis’ royalty in Biogen’s SPINRAZA®

NEW YORK, NY, January 4, 2023 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 11:15 a.m. ET / 8:15 a.m. PT. 

NEW YORK, NY, December 15, 2022 - Royalty Pharma plc (Nasdaq: RPRX) today announced the expansion of its senior leadership team . This expansion highlights Royalty Pharma’s success in developing a talented, diverse and experienced

NEW YORK , NY,  November 28, 2022 - Royalty Pharma plc (Nasdaq: RPRX) today announced that it is scheduled to participate in a fireside chat at the Evercore ISI 5^th Annual HealthCONx Virtual Conference on November 30, 2022 at 10:30 a.m. ET .

NEW YORK, NY, and PASADENA, CA, November 9, 2022 – Royalty Pharma plc (Nasdaq: RPRX) and Arrowhead today announced that Royalty Pharma has acquired a royalty interest in Amgen’s olpasiran from Arrowhead Pharmaceuticals (Nasdaq: ARWR) for $250 million in cash

NEW YORK , NY,  November 08, 2022  -  Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the third quarter of 2022 and raised full-year 2022 guidance for Adjusted Cash Receipts⁽¹⁾ (a non-GAAP financial measure).

NEW YORK, NY, October 18, 2022 – Royalty Pharma plc (Nasdaq: RPRX) today announced that it will report its third quarter 2022 financial results on Tuesday, November 8, 2022 before the U.S. financial markets open. The company will host a conference call and simultaneous webcast at 8:00 a.m.

NEW YORK, NY, October 17, 2022 – The board of directors of Royalty Pharma plc (Nasdaq: RPRX) has approved the payment of a dividend for the fourth quarter of 2022 of $0.19 per Class A ordinary share. The dividend will be paid on December 15, 2022, to shareholders of record at the close of business

NEW YORK, NY, October 12, 2022 - Royalty Pharma plc (Nasdaq: RPRX) today announced that it has entered into an agreement with Merck, known as MSD outside the United States and Canada, to co-fund the development of MK-8189, an

NEW YORK, NY, October 12, 2022 - Royalty Pharma plc (Nasdaq: RPRX) today announced an expansion of its leadership team . Art McGivern has joined Royalty Pharma as Executive Vice President, Investments & General Counsel and George Lloyd has been promoted to Executive Vice President, Investments & Chief Legal Officer.